BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Abstract Metastatic BRAF V600E colorectal cancer (CRC) carries an extremely poor prognosis and is in urgent need of effective new treatments. While the BRAFV600E inhibitor encorafenib in combination with the EGFR inhibitor cetuximab (Enc+Cet) was recently approved for this indication, overall surviv...

Full description

Bibliographic Details
Main Authors:	Laura J. Jenkins, Ian Y. Luk, Fiona Chionh, Tao Tan, Kristen Needham, Jamieson Ayton, Camilla M. Reehorst, Natalia Vukelic, Oliver M. Sieber, Dmitri Mouradov, Peter Gibbs, David S. Williams, Niall C. Tebbutt, Jayesh Desai, Frédéric Hollande, Amardeep S. Dhillon, Erinna F. Lee, Delphine Merino, W. Douglas Fairlie, John M. Mariadason
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-03-01
Series:	Cell Death and Disease
Online Access:	https://doi.org/10.1038/s41419-024-06478-z

Similar Items

PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation
by: Candani S. A. Tutuka, et al.
Published: (2017-06-01)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
by: Dolinsek Tanja, et al.
Published: (2016-09-01)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
by: Gulietta M. Pupo, et al.
Published: (2017-05-01)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
by: Julie Delyon, et al.
Published: (2023-05-01)

Inhibitors of BRAF dimers using an allosteric site
by: Xiomaris M. Cotto-Rios, et al.
Published: (2020-09-01)

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
by: Jessie Villanueva, et al.
Published: (2013-09-01)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
by: Muna Al Hashmi, et al.
Published: (2020-05-01)

Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease
by: Christopher Cronin, et al.
Published: (2022-12-01)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
by: Hima Patel, et al.
Published: (2021-11-01)

BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions
by: Ilaria Proietti, et al.
Published: (2020-07-01)

Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
by: Azad Saei, et al.
Published: (2018-09-01)

BRAF mutation and its inhibitors in sarcoma treatment
by: Haotian Liu, et al.
Published: (2020-07-01)

<i>BRAF</i> Inhibitors in <i>BRAF-Mutated</i> Colorectal Cancer: A Systematic Review
by: Wajeeha Aiman, et al.
Published: (2023-12-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
by: I. V. Samoylenko, et al.
Published: (2017-11-01)

Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study
by: Xing Liu, et al.
Published: (2021-04-01)

The path of least resistance: enhancing the effectiveness of BRAF inhibitors.
by: Goding, C
Published: (2013)

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
by: Paola Savoia, et al.
Published: (2020-12-01)

Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients
by: Martin Salzmann, et al.
Published: (2020-10-01)

BRAF Inhibitors in Non-Small Cell Lung Cancer
by: Vincenzo Sforza, et al.
Published: (2022-10-01)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
by: Mattia Garutti, et al.
Published: (2022-12-01)

Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma
by: Azad Saei, et al.
Published: (2019-08-01)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in <i>BRAF</i>V600 Melanoma: Current Status and Future Perspectives
by: Michèle Welti, et al.
Published: (2022-11-01)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant Melanoma
by: Omid Hamid, et al.
Published: (2019-10-01)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
by: Ken Saijo, et al.
Published: (2022-08-01)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
by: Francesca Del Bufalo, et al.
Published: (2018-11-01)

Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors
by: Martin L. Sos, et al.
Published: (2014-08-01)

Clinico-economic analysis of PD-1 inhibitors and combinations of BRAF and MEK inhibitors for the treatment of metastatic melanoma with a BRAF V600 gene mutation
by: D. Yu. Belousov, et al.
Published: (2018-07-01)

Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis
by: Siin Kim, et al.
Published: (2018-04-01)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
by: Ting Xu, et al.
Published: (2022-06-01)

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
by: Teresa Żołek, et al.
Published: (2023-07-01)

Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy
by: Gabrielle Giet, et al.
Published: (2019-04-01)

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
by: Sarah J. Welsh, et al.
Published: (2015-03-01)

Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations
by: Erik Hahn, et al.
Published: (2023-12-01)

The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
by: Silvia Mezi, et al.
Published: (2023-09-01)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
by: Emmanuelle M. Ruiz, et al.
Published: (2023-05-01)

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
by: Bacchiocchi Antonella, et al.
Published: (2010-07-01)

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
by: Evelina Miele, et al.
Published: (2020-02-01)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
by: Lisa Zimmer, et al.
Published: (2022-07-01)

Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
by: Tomer Meirson, et al.
Published: (2020-06-01)

Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
by: Ilaria Proietti, et al.
Published: (2020-09-01)